DNA sequencing can identify mutations that predict recurrence of renal cell carcinoma and may help low-risk patients avoid unnecessary treatment, a study finds. A synonymous mutation in the tumor ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

Renal cell carcinoma usually presents as a solid mass ... layer of flattened low cuboidal or hobnail benign epithelium. Clear cell papillary RCC is usually cystic, with cyst walls lined by ...

Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers ...

Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC ... At present, there is no clear evidence of superiority of either sequence (TKI ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

A podium presentation titled “Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead programme, IB-T101, for clear cell renal cell carcinoma (ccRCC). The trial ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.